CD8αβ+ Lymphocyte Subsets: MF (25%, 75%)
| Assessed Subset . | HIV-1 Seronegative n = 11 . | HIV-1 Seropositive (>200 CD4) n = 11 . | HIV-1 Seropositive (<200 CD4) n = 11 . |
|---|---|---|---|
| HLA-DR | |||
| + | 29 (29, 35) 3-150 | 18 (15, 22) | 15 (13, 17) |
| − | 45 (40, 53) | 21 (17, 25) | 16 (13, 18) |
| C1.7 | |||
| + | 31 (26, 37) 3-150 | 19 (19, 22) 3-150 | 15 (13, 15) |
| − | 48 (38, 55) | 25 (20, 27) | 18 (16, 23) |
| CD11a | |||
| + | 29 (24, 32) 3-150 | 18 (17, 20) 3-150 | 15 (13, 18) 3-150 |
| − | 52 (50, 71) | 31 (25, 35) | 24 (22, 32) |
| CD28 | |||
| + | 42 (42, 49) 3-150 | 28 (21, 30) 3-150 | 21 (19, 25) 3-150 |
| − | 29 (25, 33) | 20 (18, 21) | 16 (13, 17) |
| CD38 | |||
| + | 50 (42, 52) | 21 (19, 22) | 17 (14, 20) |
| − | 42 (36, 47) | 23 (21, 26) | 21 (17, 23) |
| CD45RA | |||
| + | 52 (46, 62) 3-150 | 22 (18, 25) | 20 (18, 22) |
| − | 28 (24, 32) | 23 (20, 24) | 16 (14, 20) |
| CD45RO | |||
| + | 27 (24, 32) 3-150 | 21 (18, 22) | 17 (13, 18) |
| − | 56 (42, 64) | 21 (18, 24) | 18 (17, 22) |
| CD49d | |||
| + | 35 (33, 42) 3-150 | 22 (19, 23) 3-150 | 18 (15, 19) |
| − | 63 (53, 77) | 31 (23, 34) | 19 (16, 33) |
| CD56 | |||
| + | 19 (17, 23) 3-150 | 14 (13, 18) 3-150 | 16 (14, 19) |
| − | 45 (40, 52) | 22 (21, 24) | 18 (15, 21) |
| CD57 | |||
| + | 22 (19, 29) 3-150 | 17 (16, 18) 3-150 | 13 (12, 14) 3-150 |
| − | 46 (43, 52) | 26 (23, 28) | 20 (18, 24) |
| CD58 | |||
| + | 31 (29, 39) 3-150 | 22 (21, 24) | 18 (15, 20) |
| − | 61 (53, 63) | 24 (20, 26) | 19 (17, 23) |
| CD62L | |||
| + | 47 (37, 56) 3-150 | 25 (21, 29) 3-150 | 20 (16, 22) |
| − | 25 (21, 30) | 20 (19, 21) | 16 (13, 17) |
| Assessed Subset . | HIV-1 Seronegative n = 11 . | HIV-1 Seropositive (>200 CD4) n = 11 . | HIV-1 Seropositive (<200 CD4) n = 11 . |
|---|---|---|---|
| HLA-DR | |||
| + | 29 (29, 35) 3-150 | 18 (15, 22) | 15 (13, 17) |
| − | 45 (40, 53) | 21 (17, 25) | 16 (13, 18) |
| C1.7 | |||
| + | 31 (26, 37) 3-150 | 19 (19, 22) 3-150 | 15 (13, 15) |
| − | 48 (38, 55) | 25 (20, 27) | 18 (16, 23) |
| CD11a | |||
| + | 29 (24, 32) 3-150 | 18 (17, 20) 3-150 | 15 (13, 18) 3-150 |
| − | 52 (50, 71) | 31 (25, 35) | 24 (22, 32) |
| CD28 | |||
| + | 42 (42, 49) 3-150 | 28 (21, 30) 3-150 | 21 (19, 25) 3-150 |
| − | 29 (25, 33) | 20 (18, 21) | 16 (13, 17) |
| CD38 | |||
| + | 50 (42, 52) | 21 (19, 22) | 17 (14, 20) |
| − | 42 (36, 47) | 23 (21, 26) | 21 (17, 23) |
| CD45RA | |||
| + | 52 (46, 62) 3-150 | 22 (18, 25) | 20 (18, 22) |
| − | 28 (24, 32) | 23 (20, 24) | 16 (14, 20) |
| CD45RO | |||
| + | 27 (24, 32) 3-150 | 21 (18, 22) | 17 (13, 18) |
| − | 56 (42, 64) | 21 (18, 24) | 18 (17, 22) |
| CD49d | |||
| + | 35 (33, 42) 3-150 | 22 (19, 23) 3-150 | 18 (15, 19) |
| − | 63 (53, 77) | 31 (23, 34) | 19 (16, 33) |
| CD56 | |||
| + | 19 (17, 23) 3-150 | 14 (13, 18) 3-150 | 16 (14, 19) |
| − | 45 (40, 52) | 22 (21, 24) | 18 (15, 21) |
| CD57 | |||
| + | 22 (19, 29) 3-150 | 17 (16, 18) 3-150 | 13 (12, 14) 3-150 |
| − | 46 (43, 52) | 26 (23, 28) | 20 (18, 24) |
| CD58 | |||
| + | 31 (29, 39) 3-150 | 22 (21, 24) | 18 (15, 20) |
| − | 61 (53, 63) | 24 (20, 26) | 19 (17, 23) |
| CD62L | |||
| + | 47 (37, 56) 3-150 | 25 (21, 29) 3-150 | 20 (16, 22) |
| − | 25 (21, 30) | 20 (19, 21) | 16 (13, 17) |
All results are expressed as median channel of MF (25th percentile, 75th percentile) of CD8αβ+ lymphocyte subset. CD8αβ+ lymphocytes were gated according to their lymphocyte light scatter characteristics and expression of CD8αβ-heterodimer.
Indicated data groups of median MF of anti-CD8αβ staining of CD8+ lymphocyte subsets showed significant differences (P < .05) using the Wilcoxon matched pairs test.